OBJECTIVE: To characterize modifications of high-density lipoprotein (HDL) in autoimmune gld mice that may be relevant to premature atherosclerosis in systemic lupus erythematosus, and to assess their relationship to specific aspects of autoimmune disease. METHODS: HDL cholesterol (HDL-C), apolipoprotein A-I (Apo A-I), paraoxonase 1 (PON1) activity, hepatic gene expression, and HDL biogenesis were measured in aging female gld and wild-type congenic mice. Autoantibodies, lymphoid organs, and cytokines were analyzed by enzyme-linked immunosorbent assay, flow cytometry, and multiplex assay, respectively. RESULTS: Plasma HDL-C, HDL Apo A-I, and HDL-associated PON1 activity were reduced in aging gld mice in association with the development of autoimmunity, independent of changes in hepatic Apo A-I and PON1 expression or HDL biogenesis. Hepatic induction of the acute-phase reactant serum amyloid A1 resulted in its incorporation into HDL in gld mice. Deletion of the lipid-sensitive receptor G2A in gld mice (G2A-/- gld) attenuated reductions in HDL-C and PON1 activity without altering hepatic Apo A-I and PON1 expression, HDL biogenesis, or levels of acute-phase proinflammatory cytokines. Plasma anti-Apo A-I autoantibodies were elevated in aging gld mice commensurate with detectable increases in Apo A-I immune complexes. Autoantibody levels were lower in aging G2A-/- gld mice compared with gld mice, and anti-Apo A-I autoantibody levels were significantly related to HDL-C concentrations (r=-0.645, P<0.00004) and PON1 activity (r=-0.555, P<0.0007) among autoimmune gld and G2A-/- gld mice. CONCLUSION: Autoantibodies against Apo A-I contribute to reducing HDL-C and PON1 activity in autoimmune gld mice independently of hepatic HDL biogenesis, suggesting that functional impairment and premature clearance of HDL immune complexes may be principal mechanisms involved.
OBJECTIVE: To characterize modifications of high-density lipoprotein (HDL) in autoimmune gld mice that may be relevant to premature atherosclerosis in systemic lupus erythematosus, and to assess their relationship to specific aspects of autoimmune disease. METHODS: HDL cholesterol (HDL-C), apolipoprotein A-I (Apo A-I), paraoxonase 1 (PON1) activity, hepatic gene expression, and HDL biogenesis were measured in aging female gld and wild-type congenic mice. Autoantibodies, lymphoid organs, and cytokines were analyzed by enzyme-linked immunosorbent assay, flow cytometry, and multiplex assay, respectively. RESULTS: Plasma HDL-C, HDL Apo A-I, and HDL-associated PON1 activity were reduced in aging gld mice in association with the development of autoimmunity, independent of changes in hepatic Apo A-I and PON1 expression or HDL biogenesis. Hepatic induction of the acute-phase reactant serum amyloid A1 resulted in its incorporation into HDL in gld mice. Deletion of the lipid-sensitive receptor G2A in gld mice (G2A-/- gld) attenuated reductions in HDL-C and PON1 activity without altering hepatic Apo A-I and PON1 expression, HDL biogenesis, or levels of acute-phase proinflammatory cytokines. Plasma anti-Apo A-I autoantibodies were elevated in aging gld mice commensurate with detectable increases in Apo A-I immune complexes. Autoantibody levels were lower in aging G2A-/- gld mice compared with gld mice, and anti-Apo A-I autoantibody levels were significantly related to HDL-C concentrations (r=-0.645, P<0.00004) and PON1 activity (r=-0.555, P<0.0007) among autoimmune gld and G2A-/- gld mice. CONCLUSION: Autoantibodies against Apo A-I contribute to reducing HDL-C and PON1 activity in autoimmune gld mice independently of hepatic HDL biogenesis, suggesting that functional impairment and premature clearance of HDL immune complexes may be principal mechanisms involved.
Authors: L Q Le; J H Kabarowski; Z Weng; A B Satterthwaite; E T Harvill; E R Jensen; J F Miller; O N Witte Journal: Immunity Date: 2001-05 Impact factor: 31.745
Authors: J Delgado Alves; P R J Ames; S Donohue; L Stanyer; J Nourooz-Zadeh; C Ravirajan; D A Isenberg; J Noorouz-Zadeh Journal: Arthritis Rheum Date: 2002-10
Authors: Weerapan Khovidhunkit; Min-Sun Kim; Riaz A Memon; Judy K Shigenaga; Arthur H Moser; Kenneth R Feingold; Carl Grunfeld Journal: J Lipid Res Date: 2004-04-21 Impact factor: 5.922
Authors: Anna Cederholm; Elisabet Svenungsson; Dominique Stengel; Guo-Zhong Fei; A Graham Pockley; Ewa Ninio; Johan Frostegård Journal: Arthritis Rheum Date: 2004-09
Authors: Brian W Parks; Roshni Srivastava; Shaohua Yu; Janusz H S Kabarowski Journal: Arterioscler Thromb Vasc Biol Date: 2009-01-22 Impact factor: 8.311
Authors: Leland L Black; Roshni Srivastava; Trenton R Schoeb; Ray D Moore; Stephen Barnes; Janusz H Kabarowski Journal: J Immunol Date: 2015-10-14 Impact factor: 5.422
Authors: David Henson; Ayman Samman Tahhan; David Nardo; Arshed Ali Quyyumi; Vincent J Venditto Journal: Arterioscler Thromb Vasc Biol Date: 2019-07-18 Impact factor: 8.311
Authors: Brian W Parks; Leland L Black; Kurt A Zimmerman; Allison E Metz; Chad Steele; Joanne E Murphy-Ullrich; Janusz H Kabarowski Journal: J Lipid Res Date: 2013-02-06 Impact factor: 5.922